Influenza Vaccine Using M2 Virus-Like Particles
Author Information
Author(s): Song Jae-Min, Wang Bao-Zhong, Park Kyoung-Mi, Van Rooijen Nico, Quan Fu-Shi, Kim Min-Chul, Jin Hyun-Tak, Pekosz Andrew, Compans Richard W., Kang Sang-Moo
Primary Institution: Emory University School of Medicine
Hypothesis
Can influenza virus-like particles containing the M2 protein induce broadly cross-protective immunity?
Conclusion
M2 VLP vaccination can induce long-lasting protective immunity against various influenza A strains.
Supporting Evidence
- Immunization with M2 VLPs induced anti-M2 antibodies binding to various influenza strains.
- Mice immunized with M2 VLPs showed 100% protection against lethal challenges with H1N1 and H3N2 viruses.
- M2 immune sera provided cross protection to naïve mice against the 2009 pandemic H1N1 virus.
- Significant levels of IgA antibodies were observed in bronchoalveolar lavage fluid after vaccination.
- M2 VLPs induced long-lasting immunity, providing protection even 7 months post-vaccination.
Takeaway
This study shows that a new type of flu vaccine made from a part of the virus can help protect against different kinds of flu for a long time.
Methodology
Mice were immunized with M2 VLPs and then challenged with various influenza viruses to assess immune response and protection.
Limitations
The study primarily involved mice, which may not fully represent human responses.
Participant Demographics
Female BALB/c mice, 6-8 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website